AHR and chronic kidney disease: Given the abundance of data indicating the benefit of AhR inhibition, in vivo, in vitro, or ex vivo, whether genetic or pharmacological, an in vivo proof of principle study examining CH223191 in a clinically relevant model of CKD that shows efficacy would be required to progress this class of drug to the next stage.